{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:23:54Z","timestamp":1784751834003,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.trsl.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:45:52Z","timestamp":1783093552000},"page":"148-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing"],"prefix":"10.1016","volume":"295","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7247-4950","authenticated-orcid":false,"given":"Lucas Maciel de Almeida","family":"Corr\u00eaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiggi Kevin Virgino","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Roberth","family":"Delmiro Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Diniz","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Rian","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sic\u00edlia Lins Peixoto","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2 Suppl","key":"10.1016\/j.trsl.2026.07.001_bib0001","first-page":"S1","article-title":"Kidney disease: improving global outcomes (KDIGO) ADPKD work group. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic Kidney disease (ADPKD)","volume":"107","year":"2025","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.trsl.2026.07.001_bib0002","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MNH.0000000000001101","article-title":"Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan","volume":"34","author":"Fang","year":"2025","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"25","key":"10.1016\/j.trsl.2026.07.001_bib0003","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.trsl.2026.07.001_bib0004","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.trsl.2026.07.001_bib0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.13291019","article-title":"Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential","volume":"15","author":"Nowak","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"16","key":"10.1016\/j.trsl.2026.07.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202501605R","article-title":"GLP-1RA semaglutide delays the progression of ADPKD through regulation of glycolysis, mitochondria function and ketosis","volume":"39","author":"Wu","year":"2025","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.trsl.2026.07.001_bib0007","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.trsl.2026.07.001_bib0008","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2215\/CJN.16871020","article-title":"Overweight and obesity and progression of ADPKD","volume":"16","author":"Nowak","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2024.02.014","article-title":"Visceral adiposity and progression of ADPKD: a cohort study of patients from the TEMPO 3:4 trial","volume":"84","author":"Nowak","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2026.07.001_bib0010","doi-asserted-by":"crossref","unstructured":"Hopp K., Catenacci V.A., Dwivedi N., et al. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. IScience. 2022;25(1):103697. https:\/\/doi.org\/10.1016\/j.isci.2021.103697.","DOI":"10.1016\/j.isci.2021.103697"},{"key":"10.1016\/j.trsl.2026.07.001_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1126055","article-title":"Metabolism-based approaches for autosomal dominant polycystic kidney disease","volume":"10","author":"Bakaj","year":"2023","journal-title":"Front Mol Biosci"},{"issue":"5","key":"10.1016\/j.trsl.2026.07.001_bib0012","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.kint.2023.02.010","article-title":"Drug repurposing in autosomal dominant polycystic kidney disease","volume":"103","author":"Zhou","year":"2023","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.trsl.2026.07.001_bib0013","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2026.07.001_bib0014","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s42003-018-0200-x","article-title":"Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways","volume":"1","author":"Podrini","year":"2018","journal-title":"Commun Biol"},{"key":"10.1016\/j.trsl.2026.07.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109495","article-title":"Metabolic reprogramming and the role of mitochondria in polycystic kidney disease","volume":"67","author":"Podrini","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.trsl.2026.07.001_bib0016","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","article-title":"Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease","volume":"5","author":"Menezes","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.trsl.2026.07.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109704","article-title":"Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease","volume":"73","author":"Song","year":"2020","journal-title":"Cell Signal"},{"issue":"11","key":"10.1016\/j.trsl.2026.07.001_bib0018","article-title":"Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial","volume":"4","author":"Cukoski","year":"2023","journal-title":"Cell Rep Med"},{"issue":"18","key":"10.1016\/j.trsl.2026.07.001_bib0019","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.3390\/nu16183216","article-title":"The influence of non-pharmacological and pharmacological interventions on the course of autosomal dominant polycystic kidney disease","volume":"16","author":"K\u0119dzierska-Kapuza","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.trsl.2026.07.001_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.981963","article-title":"Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.trsl.2026.07.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109648","article-title":"Molecular pathways involved in injury-repair and ADPKD progression","volume":"72","author":"Formica","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.trsl.2026.07.001_bib0022","unstructured":"ClinicalTrials.gov. Glucagon-like peptide-1 receptor agonist in ADPKD. https:\/\/clinicaltrials.gov\/study\/NCT06582875. Accessed Apr 11, 2026."},{"issue":"2","key":"10.1016\/j.trsl.2026.07.001_bib0023","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.trsl.2026.07.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.40286","article-title":"GLP1R gene expression and kidney disease progression","volume":"7","author":"Triozzi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.trsl.2026.07.001_bib0025","doi-asserted-by":"crossref","first-page":"F1647","DOI":"10.1152\/ajprenal.00082.2009","article-title":"Regulation of Na+\/H+ exchanger NHE3 by the glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells","volume":"297","author":"Carraro-Lacroix","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2026.07.001_bib0026","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2147\/DMSO.S353717","article-title":"The protective effect of glucagon-like peptide-1 receptor agonist on diabetic kidney disease via anti-inflammatory mechanism","volume":"15","author":"Li","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.001_bib0027","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.trsl.2026.07.001_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167060","article-title":"GLP-1 receptor agonist alleviates diabetic nephropathy by attenuating renal tubular ferroptosis via enhancing AMPK\/fatty acid metabolic signaling","volume":"1870","author":"Shen","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"4","key":"10.1016\/j.trsl.2026.07.001_bib0029","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.trsl.2026.07.001_bib0030","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.trsl.2026.07.001_bib0031","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1681\/ASN.2015030231","article-title":"2-Deoxy-d-glucose ameliorates PKD progression","volume":"27","author":"Chiaravalli","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.trsl.2026.07.001_bib0032","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.trsl.2026.07.001_bib0033","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.kint.2023.01.026","article-title":"A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of autosomal dominant polycystic kidney disease","volume":"103","author":"Gluais Dagorn","year":"2023","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.001_bib0034","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.trsl.2026.07.001_bib0035","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.trsl.2026.07.001_bib0036","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ckj\/sfaa232","article-title":"A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease","volume":"14","author":"Blazer-Yost","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.trsl.2026.07.001_bib0037","article-title":"Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease","volume":"2010","author":"Blazer-Yost","year":"2010","journal-title":"Int J Cell Biol"},{"issue":"10","key":"10.1016\/j.trsl.2026.07.001_bib0038","article-title":"Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease","volume":"11","author":"Oto","year":"2023","journal-title":"Physiol Rep"},{"issue":"3","key":"10.1016\/j.trsl.2026.07.001_bib0039","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/biomedicines13030635","article-title":"Metformin use and clinical outcomes in autosomal dominant polycystic kidney disease: a nationwide cohort study","volume":"13","author":"Kuo","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.trsl.2026.07.001_bib0040","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12882-025-04217-w","article-title":"Can GLP-1 receptor agonists slow the progression of autosomal dominant polycystic kidney disease?","volume":"26","author":"Ali","year":"2025","journal-title":"BMC Nephrol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193152442600143X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193152442600143X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:53:38Z","timestamp":1784750018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193152442600143X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S193152442600143X"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.07.001","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}